Skip NavigationSkip to Content
Return Return to Search Results

Genetic protection against hepatitis B virus conferred by CCR5 Delta 32: Evidence that CCR5 contributes to viral persistence

  1. Author:
    Thio, C. L.
    Astemborski, J.
    Bashirova, A.
    Mosbruger, T.
    Greer, S.
    Witt, M. D.
    Goedert, J. J.
    Hilgartner, M.
    Majeske, A.
    O'Brien, S. J.
    Thomas, D. L.
    Carrington, M.

  2. Author Address

    NCI, Lab Genom Divers, SAIC Frederick Inc, Frederick, MD 21702 USA. Johns Hopkins Univ, Dept Med, Baltimore, MD USA. Harbor UCLA, Los Angeles Biomed Res Inst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD USA. New York Presbyterian Hosp, Cornell Med Ctr, Dept Pediat, New York, NY USA.;Carrington, M, NCI, Lab Genom Divers, SAIC Frederick Inc, POB B, Frederick, MD 21702 USA.;carringt@ncifcrf.gov
    1. Year: 2007
    2. Date: Jan
  2. Journal: Journal of Virology
    1. 81
    2. 2
    3. Pages: 441-445
  4. Type of Article: Article
  5. ISSN: 0022-538X
  1. Abstract:

    Recovery from acute hepatitis B virus (HBV) infection requires a broad, vigorous T-cell response, which is enhanced in mice when chemokine receptor 5 (CCR5) is missing. To test the hypothesis that production of a nonfunctional CCR5 (CCR5 Delta 32 [a functionally null allele containing a 32-bp deletion]) increases the likelihood of recovery from hepatitis B in humans, we studied 526 persons from three cohorts in which one person with HBV persistence was matched to two persons who recovered from an HBV infection. Recovery or persistence was determined prior to availability of lamivudine. We determined genotypes for CCR5 Delta 32 and for polymorphisms in the CCR5 promoter and in coding regions of the neighboring genes, chemokine receptor 2 (CCR2) and chemokine receptor-like 2 (CCRL2). Allele and haplotype frequencies were compared among the 190 persons with viral recovery and the 336 with persistence by use of conditional logistic regression. CCR5 Delta 32 reduced the risk of developing a persistent HBV infection by nearly half (odds ratio [OR], 0.53; 95% confidence interval [CI], 0.33 to 0.83; P = 0.006). This association was virtually identical in persons with and without a concomitant human immunodeficiency virus infection. Of the nine individuals who were homozygous for the deletion, eight recovered from infection (OR, 0.25; 95% CI, 0.03 to 1.99; P = 0.19). None of the other neighboring polymorphisms examined were associated with HBV outcome. These data demonstrate a protective effect of CCR5 Delta 32 in recovery from an HBV infection, provide genetic epidemiological evidence for a role of CCR5 in the immune response to HBV, and suggest a potential therapeutic treatment for patients persistently infected with HBV.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1128/jvi.01897-06
  3. View record in Web of Science®
  4. WOS: 000243350100001

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel